Some years later, it was reported that the baseline serum levels of soluble NKG2DLs (ULBP-1 or -2) could discriminate melanoma patients treated with anti-CTLA-4 mAb plus chemotherapy with improved (median 33.6 months) or poor (median 9.8 or 6.6 months, respectively) OS [21]. Here, CTLA4 is linked to melanoma.